Summary
25.94 0.25(0.95%)06/28/2024
Arrowhead Pharmaceuticals Inc. (ARWR)
Arrowhead Pharmaceuticals Inc. (ARWR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.91 | 1.67 | 8.45 | -9.32 | -16.34 | -29.75 | -2.13 | -99.11 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.94 | |
| Open | 25.76 | |
| High | 26.04 | |
| Low | 24.88 | |
| Volume | 725,522 | |
| Change | 0.24 | |
| Change % | 0.91 | |
| Avg Volume (20 Days) | 845,802 | |
| Volume/Avg Volume (20 Days) Ratio | 0.86 | |
| 52 Week Range | 20.67 - 39.83 | |
| Price vs 52 Week High | -34.89% | |
| Price vs 52 Week Low | 25.47% | |
| Range | 0.68 | |
| Gap Up/Down | -0.65 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,228 | |
| EBIDTA | -458,108,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -1.3200 | |
| WallStreet Target Price | 55.38 | |
| Book Value | 3.8970 | |
| Earnings Per Share | -2.7700 | |
| EPS Estimate Current Quarter | -0.1600 | |
| EPS Estimate Next Quarter | -0.6300 | |
| EPS Estimate Current Year | -2.7500 | |
| EPS Estimate Next Year | -2.7200 | |
| Diluted EPS (TTM) | -2.7700 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -13.3558 | |
| Return on asset (TTM) | -0.3207 | |
| Return on equity (TTM) | -0.9943 | |
| Revenue TTM | 35,473,000 | |
| Revenue per share TTM | 0.3190 | |
| Quarterly Revenue Growth (YOY) | -0.9430 | |
| Quarterly Earnings Growth (YOY) | 0.0980 | |
| Gross Profit (TTM) | 240,735,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 111.1111 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 19.0781 | |
| Revenue Enterprise Value | 16.2790 | |
| EBITDA Enterprise Value | -11.0198 | |
| Shares | ||
| Shares Outstanding | 124,200,000 | |
| Shares Float | 119,180,093 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 4.48 | |
| Institutions (%) | 68.31 | |
06/28 06:50 EST - investorplace.com
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.
06/25 14:01 EST - businesswire.com
Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course
SYDNEY--(BUSINESS WIRE)--Canva, the world's leading visual communication platform, continues to experience significant growth in its global K-12 and higher education user base, adding 40 million users in the past year alone. With 70 million teachers and students now onboard, comprising nearly half of Canva's total users, this growth is driven by AI integration and visual communication adoption across prominent institutions like the University of California, New York City Public Schools, and the.
Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course
SYDNEY--(BUSINESS WIRE)--Canva, the world's leading visual communication platform, continues to experience significant growth in its global K-12 and higher education user base, adding 40 million users in the past year alone. With 70 million teachers and students now onboard, comprising nearly half of Canva's total users, this growth is driven by AI integration and visual communication adoption across prominent institutions like the University of California, New York City Public Schools, and the.
06/25 13:55 EST - businesswire.com
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-.
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-.
06/24 07:30 EST - businesswire.com
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been ide.
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been ide.
06/03 07:30 EST - businesswire.com
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducin.
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducin.
05/31 07:30 EST - businesswire.com
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST Session: Poster Section Jefferies Global Healthcare Conference – June 5-6, 2024 Type: Fi.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST Session: Poster Section Jefferies Global Healthcare Conference – June 5-6, 2024 Type: Fi.
05/29 05:30 EST - businesswire.com
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the.
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the.
05/28 06:04 EST - businesswire.com
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia. Treatment with plozasiran in the MUIR study achieved reductions in triglyceride rich lipoproteins, a genetically validated target associated with increased risk of atherosclerotic cardiovascular disease (ASCVD)1,2. These data were presented in an or.
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia. Treatment with plozasiran in the MUIR study achieved reductions in triglyceride rich lipoproteins, a genetically validated target associated with increased risk of atherosclerotic cardiovascular disease (ASCVD)1,2. These data were presented in an or.
05/20 07:14 EST - https://www.defenseworld.net
Panagora Asset Management Inc. Decreases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Panagora Asset Management Inc. lessened its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 58.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,262 shares of the biotechnology company’s stock after selling 121,831 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.08% of Arrowhead Pharmaceuticals worth $2,609,000 at the end of the most recent quarter. Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Arrowhead Pharmaceuticals by 58.2% during the 3rd quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company’s stock worth $115,780,000 after acquiring an additional 1,584,425 shares in the last quarter. Invesco Ltd. increased its stake in Arrowhead Pharmaceuticals by 9.6% in the third quarter. Invesco Ltd. now owns 2,443,038 shares of the biotechnology company’s stock valued at $65,644,000 after purchasing an additional 214,618 shares during the last quarter. Avidity Partners Management LP increased its stake in Arrowhead Pharmaceuticals by 15.0% in the third quarter. Avidity Partners Management LP now owns 1,063,897 shares of the biotechnology company’s stock valued at $28,587,000 after purchasing an additional 138,897 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in Arrowhead Pharmaceuticals by 3.0% during the third quarter. Eagle Asset Management Inc. now owns 497,474 shares of the biotechnology company’s stock worth $13,367,000 after purchasing an additional 14,499 shares in the last quarter. Finally, UBS Group AG lifted its position in shares of Arrowhead Pharmaceuticals by 11.7% during the 3rd quarter. UBS Group AG now owns 369,602 shares of the biotechnology company’s stock worth $9,931,000 after buying an additional 38,632 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In A number of research analysts recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 7th. Morgan Stanley dropped their price objective on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a report on Monday, May 13th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, May 13th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 10th. Finally, Citigroup boosted their price objective on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.00. Read Our Latest Stock Analysis on Arrowhead Pharmaceuticals Insider Transactions at Arrowhead Pharmaceuticals In related news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the sale, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total value of $1,407,600.00. Following the completion of the transaction, the chief financial officer now directly owns 400,600 shares of the company’s stock, valued at $14,097,114. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The disclosure for this sale can be found here. Company insiders own 4.50% of the company’s stock. Arrowhead Pharmaceuticals Stock Down 0.9 % Arrowhead Pharmaceuticals stock opened at $24.77 on Monday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $20.67 and a twelve month high of $39.83. The stock has a 50 day moving average of $25.47 and a two-hundred day moving average of $28.72. Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same quarter last year, the business earned $0.45 EPS. Arrowhead Pharmaceuticals’s revenue was down 100.0% compared to the same quarter last year. Analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current fiscal year. Arrowhead Pharmaceuticals Profile (Free Report) Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Panagora Asset Management Inc. Decreases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Panagora Asset Management Inc. lessened its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 58.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,262 shares of the biotechnology company’s stock after selling 121,831 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.08% of Arrowhead Pharmaceuticals worth $2,609,000 at the end of the most recent quarter. Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Arrowhead Pharmaceuticals by 58.2% during the 3rd quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company’s stock worth $115,780,000 after acquiring an additional 1,584,425 shares in the last quarter. Invesco Ltd. increased its stake in Arrowhead Pharmaceuticals by 9.6% in the third quarter. Invesco Ltd. now owns 2,443,038 shares of the biotechnology company’s stock valued at $65,644,000 after purchasing an additional 214,618 shares during the last quarter. Avidity Partners Management LP increased its stake in Arrowhead Pharmaceuticals by 15.0% in the third quarter. Avidity Partners Management LP now owns 1,063,897 shares of the biotechnology company’s stock valued at $28,587,000 after purchasing an additional 138,897 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in Arrowhead Pharmaceuticals by 3.0% during the third quarter. Eagle Asset Management Inc. now owns 497,474 shares of the biotechnology company’s stock worth $13,367,000 after purchasing an additional 14,499 shares in the last quarter. Finally, UBS Group AG lifted its position in shares of Arrowhead Pharmaceuticals by 11.7% during the 3rd quarter. UBS Group AG now owns 369,602 shares of the biotechnology company’s stock worth $9,931,000 after buying an additional 38,632 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In A number of research analysts recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 7th. Morgan Stanley dropped their price objective on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a report on Monday, May 13th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, May 13th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 10th. Finally, Citigroup boosted their price objective on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.00. Read Our Latest Stock Analysis on Arrowhead Pharmaceuticals Insider Transactions at Arrowhead Pharmaceuticals In related news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the sale, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total value of $1,407,600.00. Following the completion of the transaction, the chief financial officer now directly owns 400,600 shares of the company’s stock, valued at $14,097,114. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The disclosure for this sale can be found here. Company insiders own 4.50% of the company’s stock. Arrowhead Pharmaceuticals Stock Down 0.9 % Arrowhead Pharmaceuticals stock opened at $24.77 on Monday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $20.67 and a twelve month high of $39.83. The stock has a 50 day moving average of $25.47 and a two-hundred day moving average of $28.72. Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same quarter last year, the business earned $0.45 EPS. Arrowhead Pharmaceuticals’s revenue was down 100.0% compared to the same quarter last year. Analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current fiscal year. Arrowhead Pharmaceuticals Profile (Free Report) Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
05/20 06:00 EST - businesswire.com
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar la.
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar la.
05/17 10:44 EST - seekingalpha.com
Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments. Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally becoming a commercial-stage company in 2025. The bar for plozasiran is set by Ionis' olezarsen in terms of APOC3 and triglyceride reductions as well as the reduction in the risk of acute pancreatitis.
Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments. Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally becoming a commercial-stage company in 2025. The bar for plozasiran is set by Ionis' olezarsen in terms of APOC3 and triglyceride reductions as well as the reduction in the risk of acute pancreatitis.
05/14 07:08 EST - investorplace.com
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.
05/09 21:23 EST - seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Chief Medical Scientist James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital Edward Tenthoff - Piper Sandler Maury Raycroft - Jefferies Brendan Smith - TD Cowen William Pickering - Bernstein Patrick Trucchio - H.C. Wainwright & Company Operator Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Chief Medical Scientist James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital Edward Tenthoff - Piper Sandler Maury Raycroft - Jefferies Brendan Smith - TD Cowen William Pickering - Bernstein Patrick Trucchio - H.C. Wainwright & Company Operator Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
04/29 07:30 EST - businesswire.com
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14, 2024, 9:30 a.m. EDT BofA Securities 2024 Healthcare Conference – May 13-16, 2024 Type: Fireside Chat Presentation Date/Time: May 16, 2024, 8:40 a.m. PDT TIDES USA 2024 – May 14-17, 2024 Title: Preclinical Pr.
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14, 2024, 9:30 a.m. EDT BofA Securities 2024 Healthcare Conference – May 13-16, 2024 Type: Fireside Chat Presentation Date/Time: May 16, 2024, 8:40 a.m. PDT TIDES USA 2024 – May 14-17, 2024 Title: Preclinical Pr.
04/26 07:30 EST - businesswire.com
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and extern.
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and extern.
04/24 16:01 EST - businesswire.com
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at https://ir.arrowheadpharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours aft.
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at https://ir.arrowheadpharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours aft.
04/24 07:30 EST - businesswire.com
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease. James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “In preclinical studies, ARO-CFB achieved deep and durable red.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease. James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “In preclinical studies, ARO-CFB achieved deep and durable red.
04/07 09:00 EST - businesswire.com
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels. These data were prese.
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels. These data were prese.
04/05 16:30 EST - investorplace.com
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
It may not be much, but the Russell 2000 Index (RUT) is up 7% in 2024. The index still sits about 20% below the all-time high it reached in November 2021.
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
It may not be much, but the Russell 2000 Index (RUT) is up 7% in 2024. The index still sits about 20% below the all-time high it reached in November 2021.